Ridolfi Irene, Lo Sardo Luca, Nicola Stefania, Borrelli Richard, Comola Ludovica, Marmora Valentina, Badiu Iuliana, Corradi Federica, Azzolina Maria Carmen Rita, Brussino Luisa
S.C.D.U. Immunology and Allergology, A.O. Ordine Mauriziano, 10128 Turin, Italy.
Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Vaccines (Basel). 2023 Oct 11;11(10):1579. doi: 10.3390/vaccines11101579.
Patients with autoimmune diseases (ADs) and primary immunodeficiencies (PIDs) are characterized by an increased risk of noninvasive and widespread infections as they are considered frail patients. In addition, many flares of the underlying disease are reported after routine vaccinations. To date, the vaccination rate in these two populations is suboptimal. According to the latest guidelines, targeted interventions are needed, such as strengthening the network of vaccination activities. Our project aimed to propose a pilot network for carrying out the recommended vaccinations in frail patients. The Allergy and Immunology Center of the Mauriziano Hospital in Turin, Italy started the "Maurivax" project, a facilitated pathway for frail patients to administer the recommended vaccinations in the setting of a dedicated structure where they could be properly followed up. From June 2022 to February 2023, 49 patients underwent a vaccination consultation: 45 of them (91.8%) were subsequently vaccinated. Among these, 36 subjects (80%) were affected by an active AD and were already in treatment with immunosuppressive therapy or about to start it. Seven patients (15.5%) had a confirmed diagnosis of PID or showed a clinical presentation that was highly suggestive of that condition. Overall, twenty-seven patients (60%) showed a high-grade immunosuppression and six (13.3%) had a low-grade immunosuppression. No patients had a disease flare within 30 days from vaccination and no severe reactions after vaccination was observed. Adherence and vaccination safety at our immunology hospital vaccine clinic dedicated to patients with ADs and PIDs were high. We propose an effective model for managing vaccinations in frail patients in a specialist hospital setting.
自身免疫性疾病(ADs)和原发性免疫缺陷(PIDs)患者的特点是发生非侵袭性和广泛性感染的风险增加,因为他们被视为体弱患者。此外,据报道,常规疫苗接种后许多潜在疾病会发作。迄今为止,这两类人群的疫苗接种率都不理想。根据最新指南,需要采取有针对性的干预措施,例如加强疫苗接种活动网络。我们的项目旨在提出一个试点网络,以便在体弱患者中开展推荐的疫苗接种。意大利都灵毛里齐亚诺医院的过敏与免疫中心启动了“Maurivax”项目,这是一条为体弱患者提供便利的途径,以便在专门的机构环境中进行推荐的疫苗接种,并对他们进行适当的随访。从2022年6月到2023年2月,49名患者接受了疫苗接种咨询:其中45人(91.8%)随后接种了疫苗。在这些人中,36名受试者(80%)患有活动性AD,并且已经在接受免疫抑制治疗或即将开始治疗。7名患者(15.5%)确诊患有PID或临床表现高度提示患有该疾病。总体而言,27名患者(60%)表现为高度免疫抑制,6名患者(13.3%)表现为低度免疫抑制。没有患者在接种疫苗后30天内出现疾病发作,也没有观察到接种疫苗后的严重反应。我们专门为ADs和PIDs患者设立的免疫医院疫苗诊所的依从性和疫苗接种安全性很高。我们提出了一种在专科医院环境中管理体弱患者疫苗接种的有效模式。